Franziska Haderk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2230818/publications.pdf

Version: 2024-02-01

22 papers	2,594 citations	840776 11 h-index	888059 17 g-index
28 all docs	28 docs citations	28 times ranked	5915 citing authors

#	Article	IF	Citations
1	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	15
2	Extracellular vesicles prime the bone marrow niche. Blood, 2021, 138, 4-6.	1.4	2
3	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology, 2021, 62, 1-12.	6.1	83
4	Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy. , 2021, , .		0
5	Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments, 2021, , .	0.3	2
6	Betacellulin drives therapy resistance in glioblastoma. Neuro-Oncology, 2020, 22, 457-469.	1.2	8
7	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell, 2020, 182, 1232-1251.e22.	28.9	371
8	Abstract PR11: Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC. , 2020, , .		0
9	B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, S27.	1.1	0
10	Immunohistochemistry to Study YAP in Human Tissue Samples. Methods in Molecular Biology, 2019, 1893, 89-95.	0.9	6
11	RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology, 2018, 20, 1064-1073.	10.3	276
12	Abstract 3993: Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF. , 2018, , .		0
13	Obstacles and opportunities in the functional analysis of extracellular vesicle RNA â€“ an ISEV position paper. Journal of Extracellular Vesicles, 2017, 6, 1286095.	12.2	561
14	Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2, .	11.9	236
15	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. Cancers, 2017, 9, 164.	3.7	26
16	CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. Blood, 2016, 128, 3217-3217.	1.4	1
17	Abstract A30: Chronic lymphocytic leukemia-derived extracellular vesicles mediate NFkB signaling and pro-inflammatory cytokine release in monocytes. , 2016, , .		0
18	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood, 2015, 126, 1106-1117.	1.4	399

#	Article	IF	Citations
19	Chronic Lymphocytic Leukemia-Exosomes Switch Endothelial and Mesenchymal Stromal Cells into Cancer-Associated Fibroblasts to Sustain Leukemic Cell Survival. Blood, 2014, 124, 2927-2927.	1.4	2
20	Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. Blood, 2014, 124, 1968-1968.	1.4	28
21	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
22	Extracellular vesicles in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1826-1830.	1.3	15